

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



## **BIOCYTOGEN PHARMACEUTICALS (BEIJING) CO., LTD.**

**百奥赛图(北京)医药科技股份有限公司**

*(A joint stock company incorporated in the People's Republic of China with limited liability)*

**(Stock Code: 2315)**

### **VOLUNTARY ANNOUNCEMENT**

## **ENTERS INTO OPTION AND LICENSE AGREEMENT WITH IDEAYA FOR POTENTIAL FIRST-IN-CLASS B7H3/PTK7 TOPO-I-PAYLOAD BISPECIFIC ADC PROGRAM**

The board (the “**Board**”) of directors (the “**Director(s)**”) of Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (the “**Company**” or “**Biocytogen**”, together with its subsidiaries, the “**Group**”) is pleased to announce that today the Company and IDEAYA Biosciences, Inc. (the common stock of which is listed on the Nasdaq Global Select Market with stock symbol “**IDYA**”, “**IDEAYA**”) has entered into an option and license agreement (the “**Agreement**”). The Agreement grants IDEAYA an option for an exclusive worldwide license from Biocytogen for a potential first-in-class B7H3/PTK7 topo-I-payload BsADC program. Under the terms of the Agreement, Biocytogen will receive an upfront fee and upon an option exercise by IDEAYA, be entitled to receive an option exercise fee, development and regulatory milestones and commercial milestone payments, as well as single-digit royalties on net sales. Total potential upfront, option exercise and milestone payments equal an aggregate of \$406.5 million, including development and regulatory milestones of \$100.0 million.

B7H3 or PTK7 has been found to be co-expressed in multiple solid tumor types, including double-digit percent prevalence in lung, colorectal, and head and neck cancers, among others. Based on pre-clinical data, the potential first-in-class B7H3/PTK7 topoisomerase-I-inhibitor-payload BsADC program has the potential to be developed as a monotherapy agent and used in combination with multiple programs in IDEAYA’s pipeline targeting DNA Damage Repair (DDR)-based therapies, including PARG inhibitor IDE161. A development candidate nomination for the B7H3/PTK7 topoisomerase-I-inhibitor payload BsADC program is targeted for the second half of 2024.

### **Information about IDEAYA**

IDEAYA is a precision medicine oncology company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. IDEAYA’s approach integrates capabilities in identifying and validating translational biomarkers with drug discovery to select patient populations most likely to benefit from its targeted therapies. IDEAYA is applying its research and drug discovery capabilities to synthetic lethality – which represents an emerging class of precision medicine targets.

To the best knowledge and belief of the Directors, as of the date of this announcement, each of IDEAYA and its ultimate beneficial owner(s) is independent of, and not connected with, the Company and its connected persons (as defined in the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”). The transactions contemplated under the Agreement do not constitute any notifiable transactions or connected transactions of the Company under the Listing Rules.

**This is a voluntary announcement made by the Company. Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.**

By order of the Board  
**Biocytogen Pharmaceuticals (Beijing) Co., Ltd.**

**Shen Yuele**

*Chairman of the Board, Chief Executive Officer and Executive Director*

Hong Kong, July 31, 2024

*As at the date of this announcement, the Board comprises Dr. Shen Yuele as chairman, chief executive officer and executive Director, Dr. Ni Jian and Dr. Zhang Haichao as executive Directors; Mr. Wei Yiliang, Dr. Zhou Kexiang and Ms. Zhang Leidi as non-executive Directors; Mr. Hua Fengmao, Dr. Yu Changyuan and Ms. Liang Xiaoyan as independent non-executive Directors.*